Compugen Reports First Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Compugen (CGEN) Reports In-Line Q1 EPS
May 6, 2020 7:20 AM EDTCompugen (NASDAQ: CGEN) reported Q1 EPS of ($0.10), in-line with the analyst estimate of ($0.10).
"We have entered 2020 well positioned and with significant momentum to advance our clinical programs that address novel, internally-discovered, drug targets for cancer immunotherapy," said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. "On the clinical front, we recently presented at AACR updated data from our ongoing Phase 1 dose escalation study of COM701 as a monotherapy and in combination with Opdivo®. These encouraging data, which include... More
